Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	At The Market Offering	Common Stock	Common Stock At The Market Offering	Additional Paid-in Capital	Additional Paid-in Capital At The Market Offering	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning balance at Dec. 31, 2022	$ 499,315		$ 19		$ 1,558,459		$ (4,327)	$ (1,054,836)
Beginning balance (in shares) at Dec. 31, 2022			191,022
Fees incurred related to issuance of common stock from at the market offering	(200)				(200)
Vesting of restricted stock (in shares)			154
Exercise of stock options	331				331
Exercise of stock options (in shares)			233
Stock-based compensation expense	8,751				8,751
Unrealized gain (loss) on marketable securities, net	2,188						2,188
Net income (loss)	(82,123)							(82,123)
Ending balance at Mar. 31, 2023	428,262		$ 19		1,567,341		(2,139)	(1,136,959)
Ending balance (in shares) at Mar. 31, 2023			191,409
Beginning balance at Dec. 31, 2023	$ 287,506		$ 20		1,625,637		(60)	(1,338,091)
Beginning balance (in shares) at Dec. 31, 2023	197,857		197,857
Issuance of common stock, net of offering costs (in shares)			21,773	150
Issuance of common stock, net of offering costs	$ 180,008	$ 1,037	$ 2		180,006	$ 1,037
Fees incurred related to issuance of common stock from at the market offering		$ (113)
Vesting of restricted stock (in shares)			386
Exercise of stock options	$ 4,929				4,929
Exercise of stock options (in shares)	1,120		1,120
Stock-based compensation expense	$ 9,092				9,092
Unrealized gain (loss) on marketable securities, net	45						45
Net income (loss)	(107,475)							(107,475)
Ending balance at Mar. 31, 2024	$ 375,142		$ 22		$ 1,820,701		$ (15)	$ (1,445,566)
Ending balance (in shares) at Mar. 31, 2024	221,286		221,286